Camptothecin anticancer drug loaded iron oxide micro and nanoparticles: Tuning targeted and sustained release of the drug in bioactive form

Current Nanoscience

Volumn 9, Issue 6, 2013, Pages 704-710

  Gokduman, Kurtulus ^a,b   Demir, Ayhan S ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Camptothecin; Cancer chemotherapy; Cell culture; Iron oxide; Microparticles; Nanoparticles; Targeted drug delivery

Indexed keywords

EID: 84894064401     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/15734137113099990076     Document Type: Article

References (30)

1. Hatefi, A.; Amsden, B. Camptothecin delivery methods. Pharm. Res., 2002, 19, 1389-1399.
2. Wall, M.E.; Wani, M. Camptothecin and Taxol: Discovery to clinic. Cancer Res., 1995, 55, 753-760.
3. Burke, T.G.; Mishra, A.K.; Wani, M.C.; Wall, M.E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 1993, 32, 5352-5364.
4. Creemers, G.J.; Lund, B.; Verweij, J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 1994, 20, 73-96.
5. Antony, S.; Kohlhagen, G.; Agama, K.; Jayaraman, M.; Cao, S.; Durrani, F.A.; Rustum, Y.M.; Cushman, M.; Pommier, Y. Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison. Mol. Pharmacol., 2005, 67, 523-530.
6. Chourpa, I.; Millot, J.; Sockalingum, G.D.; Riou, J.; Manfait, M. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim. Biophys. Acta, 1998, 1379, 353-366.
7. 4nanoparticles for camptothecin loading and release. Acta Biomater., 2009, 5, 1489-1498.
8. Sætern, A.M.; Skar, M.; Braaten, A.; Brandl, M. Camptothecin-catalyzed phospholipid hydrolysis in liposomes. Int. J. Pharm., 2005, 288, 73-80.
9. Min, K.H.; Park, K.; Kim, Y.; Bae, S.M.; Lee, S.; Jo, H.G.; Park, R.; Kim, I.; Jeong, S.Y.; Kim, K.; Kwon, I.C. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release, 2008, 127, 208-218.
10. Ziomkowska, B.; Kruszewski, S.; Siuda, R.; Cyrankiewicz, M. Deactivation rate of camptothecin determined by factor analysis of steady-state fluorescence and absorption spectra. Opt. Appl., 2006, 36, 137-146.
11. Demir, A.S.; Tanyeli, C.; Burke, T.; Chavan, A.; Jang, T.; Pommier, Y. Water soluble derivatives of Camptothecin and homocamptothechin. US Patent, 6,291,676, September 18, 2001.
12. Yang, D.; Demir, A.S.; Chavan, A.; Burke, T.G. Oligonucleotide Delivery Systems for Camptothecins. US Patent, 6,897,200 May, 2005.
13. Madden, T.D.; Demir, A.S.; Burke, T.G.; Redelmeier, T.E.; Bally, M.B. Encapsulation of topotecan in lipid-based carrier systems. Physical formulation, evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16 tumors. Ann. Oncol., 1998, 9, 46.
14. Mert, O.; Esendagli, G.; Dogan, A.L.; Demir, A.S. Injectable biodegradable polymeric system for preserving the active form and delayed-release of camptothecin anticancer drugs. RSC Adv., 2012, 2, 176-185.
15. Gupta, A.M.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005, 26, 3995-4021.
16. Lee, Y.T.; Woo, K.; Choi, K. Preparation of Water-Dispersible and Biocompatible Iron Oxide Nanoparticles for MRI Agent. IEEE Trans. Nanotechnol., 2008, 7, 111-114.
17. Wu, W.; He, Q.; Jiang, C. Magnetic Iron Oxide Nanoparticles: Synthesis and Surface Functionalization Strategies. Nanoscale Res. Lett., 2008, 3, 397-415.
18. Mahmoudi, M.; Simchi, A.; Imani, M.; Milani, S.; Stroeve, P. Optimal Design and Characterization of Superparamagnetic Iron Oxide Nanoparticles Coated with Polyvinyl Alcohol for Targeted Delivery and Imaging. J. Phys. Chem. B, 2008, 112, 14470-14481.
19. Gao, J.; Gu, H.; Xu, B. Multifunctional Magnetic Nanoparticles: Design, Synthesis, and Biomedical Applications. Acc. Chem. Res., 2009, 42, 1097-1107.
20. Warner, D.L.; Burke, T.G. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B, 1996, 691, 161-171.
21. Stano, P.; Bufali, S.; Pisano, C.; Bucci, F.; Barbarino, M.; Santeniello, M.; Carminati, P.; Luisi, P.L. Novel Camptothecin Analogue (Gimatecan)-Containing Liposomes Prepared by the Ethanol Injection Method. J. Liposome Res., 2004, 14, 87-109.
22. Skehan, P.; Streng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst., 1990, 82, 1107-1112.
23. Jain, T.K.; Morales, M.A.; Sahoo, S.K.; Leslie-Pelecky, D.L.; Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm., 2005, 2, 194-205.
24. Gou, M.L.; Qian, Z.Y.; Wang, H.; Tang, Y.B.; Huang, M.J.; Kan, B.; Wen, Y.J.; Dai, M.; Li, X.Y.; Gong, C.Y.; Tu, M.J. Preparation and characterization of magnetic poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) microspheres. J. Mater. Sci.: Mater. Med., 2008, 19, 1033-1041.
25. Si, S.; Kotal, A.; Mandal, T.K.; Giri, S.; Nakamura, H.; Kohara, T. Sizecontrolled synthesis of magnetite nanoparticles in the presence of polyelectrolytes. Chem. Mater., 2004, 16, 3489-3496.
26. Sasaki, Y.; Yoshida, Y.; Sudoh, K.; Hakusui, H.; Fujii, H.; Ohtsu, T.; Wakita, H.; Igarashi, T.; Kuniaki, I. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer. Res., 1995, 86, 111-116.
27. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
28. Cheng, L.; Hostetler, K.Y.; Lee, J.; Koh, H.J.; Beadle, J.R.; Bessho, K.; Toyoguchi, M.; Aldern, K.; Bovet, J.; Freeman, W.R. Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir. Invest. Ophthalmol. Vis. Sci., 2004, 45, 4138-4144.
29. Kim, I.; Kim, S. Development of a polymeric nanoparticulate drug delivery system: In vitro characterization of nanoparticles based on sugar-containing conjugates. Int. J. Pharm., 2002, 245, 67-73.
30. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug. Discov., 2008, 7, 771-782.